12 studies found for:    "Pyoderma gangrenosum"
Show Display Options
Rank Status Study
1 Completed Proof of Concept Study of Gevokizumab in the Treatment of Pyoderma Gangrenosum
Condition: Pyoderma Gangrenosum
Intervention: Drug: gevokizumab
2 Terminated A 2-Year, Open-Label, Safety Extension Study of Gevokizumab in Subjects With Pyoderma Gangrenosum
Condition: Pyoderma Gangrenosum
Intervention: Drug: gevokizumab
3 Terminated An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum
Condition: Pyoderma Gangrenosum
Interventions: Drug: gevokizumab;   Drug: Placebo;   Drug: gevokizumab open-label
4 Terminated An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum
Condition: Pyoderma Gangrenosum
Interventions: Drug: gevokizumab;   Drug: Placebo;   Drug: gevokizumab open-label
5 Recruiting RA-18C3 Therapy for Subjects With Pyoderma Gangrenosum
Condition: Pyoderma Gangrenosum
Intervention: Biological: RA-18C3
6 Unknown  Canakinumab for Pyoderma Gangrenosum
Condition: Pyoderma Gangrenosum
Intervention: Drug: Canakinumab
7 Withdrawn Safety and Efficacy Study of Humira in Treatment of Pyoderma Gangrenosum
Condition: Pyoderma Gangrenosum
Intervention: Drug: Humira
8 Recruiting Single-arm Study to Assess a Potential Effect of Anti-IL-17 (Secukinumab) in the Treatment of Pyoderma Gangrenosum
Condition: Pyoderma Gangrenosum
Intervention: Drug: Secukinumab
9 Withdrawn Study to Determine the Safety and Efficacy of Adalimumab in the Treatment of Pyoderma Gangrenosum
Condition: Pyoderma Gangrenosum
Intervention: Drug: adalimumab
10 Completed
Has Results
Open Label Study for Adults With Pyoderma Gangrenosum and Inflammatory Bowel Disease
Conditions: Pyoderma Gangrenosum;   Crohn's Disease;   Ulcerative Colitis;   Inflammatory Bowel Disease
Intervention: Drug: Infliximab
11 Recruiting Observational Study of the Genetic Architecture of Neutrophil-Mediated Inflammatory Skin Diseases
Conditions: Other Specified Inflammatory Disorders of Skin or Subcutaneous Tissue;   Pyoderma Gangrenosum;   Erosive Pustular Dermatosis of the Scalp;   Sweet's Syndrome;   Behcet's Disease;   Bowel-associated Dermatosis-arthritis Syndrome;   Pustular Psoriasis;   Acute Generalized Exanthematous Pustulosis;   Keratoderma Blenorrhagicum;   Sneddon-Wilkinson Disease;   IgA Pemphigus;   Amicrobial Pustulosis of the Folds;   Infantile Acropustulosis;   Transient Neonatal Pustulosis;   Neutrophilic Eccrine Hidradenitis;   Rheumatoid Neutrophilic Dermatitis;   Neutrophilic Urticaria;   Still's Disease;   Erythema Marginatum;   Unclassified Periodic Fever Syndromes / Autoinflammatory Syndromes;   Dermatitis Herpetiformis;   Linear IgA Bullous Dermatosis;   Bullous Systemic Lupus Erythematosus;   Inflammatory Epidermolysis Bullosa Aquisita;   Neutrophilic Dermatosis of the Dorsal Hands (Pustular Vasculitis);   Small Vessel Vasculitis Including Urticarial Vasculitis;   Erythema Elevatum Diutinum;   Medium Vessel Vasculitis
Intervention: Procedure: Collection of biological samples
12 Completed Topical Tacrolimus 0.1% Ointment For Treatment Of Cutaneous Crohn's Disease
Condition: Crohn Disease
Intervention: Drug: Tacrolimus

Indicates status has not been verified in more than two years